<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391051</url>
  </required_header>
  <id_info>
    <org_study_id>FOKAL-BT</org_study_id>
    <nct_id>NCT02391051</nct_id>
  </id_info>
  <brief_title>Focal Brachytherapy in Patients With Selected &quot;Low-risk&quot; Prostate Cancer - a Phase-II-trial</brief_title>
  <acronym>FOKAL-BT</acronym>
  <official_title>Focal Brachytherapy in Patients With Selected &quot;Low-risk&quot; Prostate Cancer - a Phase-II-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial examines the feasibility and toxicity of focal brachytherapy in patients with
      low-risk prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with low-risk prostate cancer will receive HDR-Brachytherapy: 2 x 13,5 Gy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity and frequency of adverse events</measure>
    <time_frame>6 weeks after therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor regression</measure>
    <time_frame>6 weeks up to 10 years after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recurrences measured by PSA</measure>
    <time_frame>10 years after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Markers RTEN, ERG, APN, Ki67, KPNA1, PSMA, FGFR1, PMP22, CDKN1A/P16, PDCD4, KLF6, PITX with PSA free survival</measure>
    <time_frame>10 years after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of microRNA141 and -375 with outcome</measure>
    <time_frame>10 years after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility, as measured by NCI-CTCAE-scale, EORTC-QLQ, IIEF, IPSS, ICIQ</measure>
    <time_frame>6 weeks after therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Focal Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HDR-Brachytherapy, 2 fractions within at least 24 but max. 30 hours, each 13,5 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR-Brachytherapy</intervention_name>
    <description>HDR-Brachytherapy 2x 13,5 Gy</description>
    <arm_group_label>Focal Brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18

          -  Histologically confirmed prostate cancer

          -  Gleason Score of index lesion ≤ 6 (3+3)

          -  Tumor stage: cT1-2a cN0 cM0

          -  Unilateral affection; index lesion ≤ 0.5ml with or without clinically non-significant
             lesion contralateral. No more than 25% of the punch should be affected. Therefore a
             3D-TPM-biopsy is mandatory before treatment.

          -  PSA ≤ 10/ng/ml

          -  Prostate volume &lt; 60 m^3

          -  No distant metastasis

          -  Life expectancy &gt; 10 years

          -  Informed consent

        Exclusion Criteria:

          -  Tumor stage ≥ T2b

          -  Known metastasis: N+ and/or M1

          -  General anesthesia or peridural anesthesia is not possible

          -  Coagulation disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vratislav Strnad, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Dept. of Radiooncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bastian Keck, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Dept. of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Cavallaro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Dept. of Radiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arndt Hartmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Dept. of Pathology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Lotter, Dipl.-Phys.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Dept. of Radiooncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annedore Strnad, MD, MHBA</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Dept. of Radiooncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Goebell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Dept. of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Uter, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Erlangen; Dept. of Biometrics and Epidemiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Uder, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Dept. of Radiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernd Wullich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Dept. of Urology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rainer Fietkau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Dept. of Radiooncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vratislab Strnad, MD</last_name>
      <phone>++49-9131-85</phone>
      <phone_ext>33968</phone_ext>
      <email>st-studiensekretariat@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Vratislav Strnad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>focal brachytherapy</keyword>
  <keyword>PSA</keyword>
  <keyword>Biological marker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

